PL2609916T3 - Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń - Google Patents

Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Info

Publication number
PL2609916T3
PL2609916T3 PL12196650T PL12196650T PL2609916T3 PL 2609916 T3 PL2609916 T3 PL 2609916T3 PL 12196650 T PL12196650 T PL 12196650T PL 12196650 T PL12196650 T PL 12196650T PL 2609916 T3 PL2609916 T3 PL 2609916T3
Authority
PL
Poland
Prior art keywords
related disorders
new therapeutic
therapeutic approaches
treating cmt
cmt
Prior art date
Application number
PL12196650T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of PL2609916T3 publication Critical patent/PL2609916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL12196650T 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń PL2609916T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
EP12196650.1A EP2609916B1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating CMT and related disorders
EP08854467A EP2211846B1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating CMT and related disorders
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
PL2609916T3 true PL2609916T3 (pl) 2019-03-29

Family

ID=39264515

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12196650T PL2609916T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń
PL08854467T PL2211846T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08854467T PL2211846T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Country Status (24)

Country Link
US (6) US8992891B2 (pl)
EP (4) EP2065038A1 (pl)
JP (4) JP5953000B2 (pl)
KR (1) KR101546031B1 (pl)
CN (2) CN104257657B (pl)
AU (1) AU2008328745B2 (pl)
BR (1) BRPI0819678A2 (pl)
CA (3) CA3031484C (pl)
CY (2) CY1113980T1 (pl)
DK (2) DK2609916T3 (pl)
EA (3) EA035711B1 (pl)
ES (3) ES2703508T3 (pl)
HR (2) HRP20130345T1 (pl)
HU (1) HUE040596T2 (pl)
IL (1) IL205741A0 (pl)
LT (1) LT2609916T (pl)
MX (1) MX2010005709A (pl)
NZ (1) NZ585440A (pl)
PL (2) PL2609916T3 (pl)
PT (2) PT2609916T (pl)
SI (2) SI2211846T1 (pl)
TR (1) TR201819564T4 (pl)
WO (1) WO2009068668A1 (pl)
ZA (1) ZA201003610B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2502079B1 (en) * 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
JP5914357B2 (ja) 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物
CA2812855C (en) * 2010-10-08 2017-12-19 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
WO2014063163A1 (en) 2012-10-19 2014-04-24 Block Jonathan D Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
KR20160126045A (ko) * 2014-02-24 2016-11-01 파넥스트 기계적 신경 손상을 치료하기 위한 신규 조성물
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
AU2017229778A1 (en) 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2018014007A1 (en) * 2016-07-14 2018-01-18 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
CA3044691A1 (en) * 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
KR20230005944A (ko) * 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
EP1020193A4 (en) 1997-09-30 2006-05-24 Daiichi Seiyaku Co ORAL PREPARATION
EP1115864A2 (en) * 1998-09-22 2001-07-18 Incyte Genomics, Inc. Human chaperone proteins
WO2000020024A2 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
AU2003220290B2 (en) * 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
PT1578350E (pt) * 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
JP2006504679A (ja) 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
KR20120066688A (ko) * 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
PL2368554T3 (pl) * 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
MXPA06003392A (es) * 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
RS53227B (sr) 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
EA201791669A2 (ru) 2017-12-29
CA3031484A1 (en) 2009-06-04
DK2609916T3 (en) 2019-01-21
US20180250289A1 (en) 2018-09-06
BRPI0819678A2 (pt) 2017-05-09
EP3459535B1 (en) 2020-08-12
JP2018109043A (ja) 2018-07-12
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
JP5953000B2 (ja) 2016-07-13
HUE040596T2 (hu) 2019-03-28
CN104257657A (zh) 2015-01-07
HRP20130345T1 (hr) 2013-07-31
EP2211846B1 (en) 2013-02-27
CA3031490C (en) 2021-05-04
EA201791669A3 (ru) 2018-03-30
AU2008328745A1 (en) 2009-06-04
EP2211846A1 (en) 2010-08-04
HRP20182147T1 (hr) 2019-03-08
DK2211846T3 (da) 2013-04-29
EA201301078A1 (ru) 2014-06-30
WO2009068668A1 (en) 2009-06-04
HRP20182147T8 (hr) 2019-04-19
KR20100088160A (ko) 2010-08-06
US10441558B2 (en) 2019-10-15
CY1121183T1 (el) 2020-05-29
CA2705408A1 (en) 2009-06-04
KR101546031B1 (ko) 2015-08-25
US20180360785A1 (en) 2018-12-20
US20200155491A1 (en) 2020-05-21
SI2211846T1 (sl) 2013-07-31
CN101883561A (zh) 2010-11-10
CN104257657B (zh) 2017-07-04
CA2705408C (en) 2019-04-23
TR201819564T4 (tr) 2019-01-21
US8992891B2 (en) 2015-03-31
ES2408785T3 (es) 2013-06-21
CA3031490A1 (en) 2009-06-04
JP2011504915A (ja) 2011-02-17
EA019402B1 (ru) 2014-03-31
EP2609916B1 (en) 2018-11-07
CN101883561B (zh) 2014-07-30
MX2010005709A (es) 2010-11-05
ES2831855T3 (es) 2021-06-09
EP3459535A1 (en) 2019-03-27
CA3031484C (en) 2021-05-04
NZ585440A (en) 2011-12-22
ES2703508T3 (es) 2019-03-11
LT2609916T (lt) 2019-02-11
IL205741A0 (en) 2010-11-30
PT2211846E (pt) 2013-05-10
AU2008328745B2 (en) 2014-01-30
US20180338969A1 (en) 2018-11-29
EA032767B1 (ru) 2019-07-31
EA035711B1 (ru) 2020-07-29
US20150157626A1 (en) 2015-06-11
ZA201003610B (en) 2011-06-29
US20100310641A1 (en) 2010-12-09
EP2609916A1 (en) 2013-07-03
PT2609916T (pt) 2019-01-10
JP2019142917A (ja) 2019-08-29
EP2065038A1 (en) 2009-06-03
CY1113980T1 (el) 2016-07-27
US10322101B2 (en) 2019-06-18
EA201000914A1 (ru) 2010-12-30
JP2016145227A (ja) 2016-08-12
US10463640B2 (en) 2019-11-05
JP6608309B2 (ja) 2019-11-20

Similar Documents

Publication Publication Date Title
HRP20182147T1 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
IL205730A0 (en) Methods for treating obesity and obesity related diseases and disorders
ZA200900734B (en) Combination treatment for metabolic disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB0918546D0 (en) Compounds for treating ophthalmic diseases and disorders
GB0602178D0 (en) Therapeutic treatment
IL222557A (en) A compound for use in treating mutant disorders has ruled
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
ZA201109423B (en) New compositions for treating cmt and related disorders
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL201422A0 (en) Therapeutic agents useful for treating pain
ZA201002167B (en) Treatment regime for proliferative disorders
EP2184598A4 (en) FABRIC PIECE TREATMENT DEVICE
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
ZA201202346B (en) Therapeutic agent for mood disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0608655D0 (en) Therapeutic Treatment
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
GB0702537D0 (en) Treatment for excessive adiposity
GB0610909D0 (en) Therapeutic treatment
IL207906A0 (en) Treatment for ocular-related disorders
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0610376D0 (en) Therapeutic treatment
ZA200905750B (en) Therapeutic agents useful for treating pain